Matthew Angel
Insider Reports History
- Location
- San Diego, CA
- Signature
- /s/ Matthew Angel
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Matthew Angel:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Tempest Therapeutics, Inc. | CEO and President, Director, 10%+ Owner | Common Stock | 8,268,495 | $23,730,580 | $2.87 | 03 Feb 2026 | By Erigen LLC |
| Tempest Therapeutics, Inc. | CEO and President, Director, 10%+ Owner | Common Stock | 4,837,070 | $13,882,390 | $2.87 | 24 Mar 2026 | Direct |
| Tempest Therapeutics, Inc. | CEO and President, Director, 10%+ Owner | Common Stock | 231,482 | $500,001 | $2.16 | 24 Mar 2026 | By Factor Bioscience Inc. |
| Tempest Therapeutics, Inc. | CEO and President, Director, 10%+ Owner | Employee Stock Option (right to buy) | 269,621 | 04 Feb 2026 | Direct | ||
| Eterna Therapeutics Inc. | President and CEO, Director | Stock Option (right to buy) | 132,003 | 12 Jan 2023 | Direct |
Insider Reports Filed by Matthew Angel
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TPST | Tempest Therapeutics, Inc. | 24 Mar 2026 | 1 | +$500,001 | 4 | CEO and President, Director, 10%+ Owner | 25 Mar 2026, 17:32 |
| TPST | Tempest Therapeutics, Inc. | 04 Feb 2026 | 1 | $0 | 4 | CEO and President, Director, 10%+ Owner | 06 Feb 2026, 16:26 |
| TPST | Tempest Therapeutics, Inc. | 03 Feb 2026 | 0 | $0 | 3 | CEO and President, Director, 10%+ Owner | 06 Feb 2026, 16:24 |
| ERNA | Eterna Therapeutics Inc. | 12 Jan 2023 | 1 | $0 | 4 | President and CEO, Director | 13 Jan 2023, 18:30 |
| ERNA | Brooklyn ImmunoTherapeutics, Inc. | 01 Aug 2022 | 1 | $0 | 4 | Interim President and CEO, Director | 03 Aug 2022, 20:01 |
| ERNA | Brooklyn ImmunoTherapeutics, Inc. | 26 May 2022 | 0 | $0 | 3 | Interim President and CEO | 01 Jun 2022, 17:00 |